Our "New in MDS" articles cover treatment option updates, coverage of advancements from MDS academic meetings, and more.
March 07, 2023
BMT “was associated with an increased risk of subsequent malignant neoplasms of the gastrointestinal (GI) tract.”
January 31, 2023
During the 64th ASH Annual Meeting, Dr. Verma outlined the various inflammatory mediators that are elevated in MDS.
January 25, 2023
Venetoclax is a BCL-2 inhibitor, meaning it blocks the action of the BCL-2 protein that helps cancer cells survive and grow.
January 18, 2023
Many factors contribute to health inequity including access to care and health insurance, cost, and education
January 04, 2023
Many centers tell stem cell transplant patients to restrict their diet after transplant to prevent infection. Stats say it doesn't make much difference.
December 10, 2022
About syndromes under the MDS umbrella, and how integrative medicine can lead to a more efficient diagnosis.
December 06, 2022
HealthTree will be on site at the annual ASH 2022 meeting to report on the latest in MDS research.
October 20, 2022
Why are there so few Myelodysplastic Syndromes (MDS) therapeutic treatment options when the majority of MDS patients require therapeutic intervention?
October 11, 2022
The IPSS-M, is a new prognostic scoring system using genomic and cytogenetic profiling, and hematologic parameters to deliver prognosis categorization.